Acadia Pharmaceuticals

Area Business Manager- Philadelphia

Philadelphia, Pennsylvania, United States

Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biopharmaceutical, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates should possess strong clinical and business acumen, with a preference for existing relationships with local endocrinologist healthcare professionals and a working knowledge of market access and local business trends. An in-depth understanding of analytics is required to identify business opportunities and create actionable business plans.

Responsibilities

The Endocrinology Area Business Manager will develop territory business plans to achieve sales goals, build relationships with healthcare professionals, drive product adoption, and educate providers on the product profile of Madrigal's therapy. Responsibilities include understanding Resmetirom's mechanism of action and clinical benefits, tailoring presentations, evaluating office readiness for patient identification and prescribing, providing education on market access and fulfillment, ensuring compliant prescription pull-through, executing promotional programs, analyzing sales data, and staying updated on clinical data and treatment guidelines.

Skills

Sales
Business Development
Territory Management
Healthcare Professional (HCP) Relationships
Product Adoption
Sales Goals Achievement
Analytics
Business Planning
Market Access
Endocrinology
Biopharmaceutical Sales

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters
1993Year Founded
$813.4MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Holidays
Paid Sick Leave
Paid Parental Leave
Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.
Potential clinical trial delays could affect drug approval timelines.
Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.
The company has a strong R&D foundation, developing innovative small molecule drugs.
Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.
Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.
The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI